Intranasal stimulator increased tear production in trials

Allergan announced that a premarket submission for Oculeve Intranasal Tear Neurostimulator will be submitted to the FDA in the second half of 2016, following two pivotal trials that met their primary and secondary efficacy endpoints.The handheld stimulator and daily disposable tips increase tear production upon stimulation in patients with dry eye disease due to decreased tear production, according to a press release from the company.